András Strassz, MD, MBA, CMO at Heidelberg Pharma – Career Crossroads, Recruiting, and Culture Fit Over CVs

András Strassz, MD, MBA, CMO at Heidelberg Pharma – Career Crossroads, Recruiting, and Culture Fit Over CVs

In this episode, I talked with Dr. András Strassz, Chief Medical Officer at Heidelberg Pharma, to hear about his two decades of leadership in oncology drug development—and the often-overlooked realities behind building teams, designing clinical trials, and making biotech work.

András opens up about key moments in his career, including the personal crisis that almost forced him to leave the industry, the turning point when he stepped into his CMO role, and what it really takes to develop first-in-class ADCs with novel payloads.

We also dive deep into industry-wide mistakes—why promising clinical programs still fail because of poor design, how pressure and under-resourcing distort decision-making, and why senior leadership continues to overlook culture fit when hiring.

András also shares behind-the-scenes insights into Heidelberg’s development of amanitin-based ADCs, what makes their team culture unique, and why “good enough” just isn’t good enough when you’re trying to build something from scratch.

(Find out more in the episode.)

Here’s What You’re In For

  • Why culture alignment should outweigh credentials when building teams
  • How to spot red flags in hiring—even before the offer stage
  • What good leadership looks like in biotech—and what it never forgets


Timestamps

02:18 – Why he left clinical practice and how he got his first pharma job at J&J

05:38 – Career highlights: relocating from Hungary and becoming CMO

09:09 – Career low point: near job loss during relocation and how he handled it

11:01 – Burnout in his first role and the health consequences of overwork

13:38 – Overview of Heidelberg Pharma’s ADC platform

15:58 – What defines the people and culture at Heidelberg

18:51 – Biggest industry mistakes: bad study design, rushed decisions, outdated models

26:00 – Hiring reflections: CV vs culture fit, and how interviews often mislead


About András

Dr. András Strassz is the Chief Medical Officer of Heidelberg Pharma, a clinical stage biopharmaceutical company specializing in antibody-drug conjugates (ADCs) for targeted cancer treatment. András specializes in early clinical development, focusing on oncology and hematological oncology. He has experience working in both Big Pharma, namely JnJ, Amgen, Novartis, and Biotechs - Polyphor, Affimed, and his current company, Heidelberg Pharma across three countries: Hungary, Germany, and Switzerland.

Outside his professional stint, his hobbies are DIY, hiking, and cooking. We have know each other for a while now, always appreciated András honesty, humour and insights and he is here to join me today - welcome.


Connect with András




About me

My name is Charles Spence and I lead Discera. After many years working in the life-science recruitment world, I decided to work for myself. Before doing recruitment I graduated with a biomedical degree, have worked in hospitals (including translation work in Seoul, South Korea), and also spent a year working in diabetes research in Stockholm. After doing research and travel, a career in business and science felt the most appropriate.

In 2023, I decided to launch my firm - Discera Search. A firm committed to solving the biggest talent needs of early clinical stage SME biotechs on the East Coast and DACH.


Connect with me:




Opinions and comments expressed by the guest do not represent the company and are fully their own.

Det här avsnittet är hämtat från ett öppet RSS-flöde och publiceras inte av Podme. Det kan innehålla reklam.

Avsnitt(74)

Eliot Forster, CEO at Levicept on 30 Years in Pharma, Running a Six-Person Biotech, and the Future of European Drug Development

Eliot Forster, CEO at Levicept on 30 Years in Pharma, Running a Six-Person Biotech, and the Future of European Drug Development

In this episode, I talked with Eliot Forster, CEO of Levicept, a neurophysiologist-turned biotech veteran with 30+ years of experience across Big Pharma and a series of CEO roles. We get into clinical...

7 Sep 45min

Michael Zaiac, Medical Affairs Lead for Oncology at Daiichi Sankyo on 30 Years of Hiring Lessons, The ADC Wave, and Building Teams in a Fast-Moving Pipeline

Michael Zaiac, Medical Affairs Lead for Oncology at Daiichi Sankyo on 30 Years of Hiring Lessons, The ADC Wave, and Building Teams in a Fast-Moving Pipeline

In this episode, I talked with Michael Zaiac, Medical Affairs Lead for Oncology across Europe and Canada at Daiichi Sankyo — a trained surgical oncologist who walked away from the operating table, mov...

24 Aug 39min

Juho Jalkanen, CEO at Faron Pharmaceuticals on From Surgeon to CEO, Rethinking Boards, and Fighting for the Right Science

Juho Jalkanen, CEO at Faron Pharmaceuticals on From Surgeon to CEO, Rethinking Boards, and Fighting for the Right Science

In this episode, I talked with Dr. Juho Jalkanen, CEO of Faron Pharmaceuticals — a publicly listed Finnish biotech building novel immunotherapies for blood cancers. Juho's path is unlike most you'll h...

10 Aug 37min

Tobias Kampfenkel, MD, MHBA, Vice President of Early Clinical Development and Translational Research at Miltenyi Biomedicine, on Transformative Drugs in Oncology and Autoimmunity: It's Always the Team!

Tobias Kampfenkel, MD, MHBA, Vice President of Early Clinical Development and Translational Research at Miltenyi Biomedicine, on Transformative Drugs in Oncology and Autoimmunity: It's Always the Team!

In this episode, I talked with Dr. Tobias Kampfenkel, Vice President of Early Clinical Development and Translational Research at Miltenyi Biomedicine. Tobias spent nearly a decade at Janssen building ...

15 Juni 39min

Sofia Heigis, CEO of OncoPeptides, From Sales Rep to CEO, Being "Present", and Hiring for Self-Insight

Sofia Heigis, CEO of OncoPeptides, From Sales Rep to CEO, Being "Present", and Hiring for Self-Insight

In this episode, I talked with Sofia Heigis, Chief Executive Officer of OncoPeptides, about a career path that did not start where she expected. Sofia originally wanted to move into clinical operation...

31 Maj 38min

Jens Lindberg, CEO at Medivir, on The Biotech Rollercoaster - Medivir´s Previous Four Months (and Biotech Today in 2026)

Jens Lindberg, CEO at Medivir, on The Biotech Rollercoaster - Medivir´s Previous Four Months (and Biotech Today in 2026)

In this episode, I talked with Jens Lindberg, CEO of Medivir AB, a Swedish biotech developing innovative therapies in liver cancer and rare disease. Jens brings over 30 years of late-stage development...

18 Maj 33min

Hubert Truebel,  Managing Director at DEBRA Research, on Creating Own Career Opportunities...and a Practical Approach to Longevity

Hubert Truebel, Managing Director at DEBRA Research, on Creating Own Career Opportunities...and a Practical Approach to Longevity

In this episode, I talked with Hubert Truebel, Managing Director at DEBRA Research, to discover a career that wasn’t built traditionally—but through creating opportunities where none formally existed....

4 Maj 28min

Sampreet Ramachandra, Head of Hematology Business Unit at Novartis Germany, on Launching Without a Playbook, Hiring Mistakes, and Leading with Equity

Sampreet Ramachandra, Head of Hematology Business Unit at Novartis Germany, on Launching Without a Playbook, Hiring Mistakes, and Leading with Equity

In this episode, I talked with Sampreet Ramachandra, Head of the Hematology Business Unit at Novartis Germany, about what it really takes to lead high-stakes launches — and what leadership looks like ...

30 Mars 42min

Populärt inom Business & ekonomi

framgangspodden
varvet
rss-jossan-nina
rss-borsens-finest
svd-tech-brief
24fragor
avanzapodden
badfluence
uppgang-och-fall
rss-inga-dumma-fragor-om-pengar
lastbilspodden
fill-or-kill
rss-dagen-med-di
rss-kort-lang-analyspodden-fran-di
rikatillsammans-om-privatekonomi-rikedom-i-livet
tabberaset
bathina-en-podcast
kapitalet-en-podd-om-ekonomi
borsmorgon
affarsvarlden